DrugPatentWatch Database Preview
NUVARING Drug Profile
see a sample report or, see our see our flat-rate plans
When do Nuvaring patents expire, and what generic alternatives are available?
Nuvaring is a drug marketed by Organon Sub Merck and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
The generic ingredient in NUVARING is ethinyl estradiol; etonogestrel. There are twenty-six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; etonogestrel profile page.
Summary for NUVARING
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 3 |
| Bulk Api Vendors: | 1 |
| Clinical Trials: | 25 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for NUVARING |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for NUVARING |
| DailyMed Link: | NUVARING at DailyMed |
Pharmacology for NUVARING
| Ingredient-type | Progesterone Congeners |
| Drug Class | Progestin Estrogen |
| Mechanism of Action | Estrogen Receptor Agonists |
US Patents and Regulatory Information for NUVARING
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organon Sub Merck | NUVARING | ethinyl estradiol; etonogestrel | RING;VAGINAL | 021187-001 | Oct 3, 2001 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
Expired US Patents for NUVARING
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Organon Sub Merck | NUVARING | ethinyl estradiol; etonogestrel | RING;VAGINAL | 021187-001 | Oct 3, 2001 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for NUVARING
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Vaginal Ring | 0.015 mg/24 hour and 0.12 mg/24 hour | ➤ Subscribe | ➤ Try a Free Trial |
see a sample report or, see our see our flat-rate plans
International Patents for NUVARING
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Japan | 4982670 | ➤ Try a Free Trial |
| Canada | 2233753 | ➤ Try a Free Trial |
| Germany | 69803112 | ➤ Try a Free Trial |
| Poland | 192449 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for NUVARING
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2006 00038 | Denmark | ➤ Try a Free Trial | PRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804 |
| C0001 | France | ➤ Try a Free Trial | PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804 |
| 2016 00016 | Denmark | ➤ Try a Free Trial | PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211 |
| 00C/027 | Belgium | ➤ Try a Free Trial | PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
